Delivery Order SPE2DB22D2218-SPE2DB25FR2GV

Award Date 4/9/25
Potential Completion Date 4/10/25
Potential Value $20K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $7,710.23 firm fixed-price delivery order is for Rinvoq ER 30 mg tablets, a medication used to treat various medical conditions. The contract has an ultimate completion date of March 28, 2025. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical,...
This federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, provides for the delivery of Rinvoq ER 15 mg tablets to the Defense Logistics Agency (DLA). The $10,495.14 firm fixed-price delivery order has a completion date of June 13, 2024. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical division, which serves as a primary vehicle for supplying a comprehensive range of pharmaceutical products and...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $37,313.23 delivery order contract is for the supply of RINVOQ ER 45 MG TABLET, a pharmaceutical product. The contract is a firm fixed-price delivery order, without any set-aside designation, indicating open competition. AmerisourceBergen Drug Corp holds a significant $999,999,999.00 Indefinite Delivery Contract...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $14,742.57 firm fixed-price delivery order contract covers the supply of RINVOQ ER 30 MG TABLET UU 30S, a pharmaceutical product. The contract has an ultimate completion date of February 19, 2025. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $29,592.12 firm-fixed-price delivery order contract is for the supply of the prescription medication Rinvoq ER 45 mg tablets. The contract has an ultimate completion date of April 22, 2025 and is not designated as a set-aside. AmerisourceBergen Drug Corp holds a significant $999,999,999.00 Indefinite Delivery...
This federal contract award from the Defense Logistics Agency (DLA) was issued to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the delivery of Rinvoq ER 30 mg tablets. The $6,379.06 firm-fixed-price delivery order has an ultimate completion date of October 18, 2024. The contract is not designated under any set-aside program, indicating open competition. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, which serves...
This is a federal contract award from the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $26,733.44 firm fixed-price delivery order is for RINVOQ ER 45 MG TABLET UU 28S, a pharmaceutical product. The contract has an ultimate completion date of November 30, 2023. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $16,153.15 firm fixed-price delivery order is for the supply of RINVOQ ER 15 MG TABLET UU 30S, a pharmaceutical product. The contract has an ultimate completion date of January 8, 2025. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, running...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $44,513.45, is for the delivery of Rinvoq ER 30 mg tablets. It is a firm fixed-price delivery order contract with an ultimate completion date of April 30, 2025. The contract is not set aside and is open for competition. AmerisourceBergen Drug Corp holds a significant Indefinite Delivery Contract...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $7,340.25 firm fixed-price delivery order is for the supply of RINVOQ ER 15 MG TABLET UU 30S, a pharmaceutical product. The contract has an ultimate completion date of March 4, 2025. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves...
  • SPE2DB22D2218
    Indefinite Delivery Contract
  • SPE2DB22D2218-SPE2DB25FR2GV
    Delivery Order

This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $20,495.18 firm fixed-price delivery order is for the drug Rinvoq ER 45 mg tablet. The contract has an ultimate completion date of April 10, 2025. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical through November 2026, which serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. This delivery order does not have a set-aside designation, indicating open competition.

Generated 7/9/25, 10:07 AM